Comparison of different cutoffs of time from last drug exposure to disease progression for defining drug refractoriness in multiple myeloma

apoptosis in cancer cell lines, and showed anti-cancer activity in vivo.The cyclic peptide Ub4a displayed stability in human plasma for multiple days, with a half-life of 60 hours, suggesting its potential for therapeutic applications.Overall, the study highlights the promising therapeutic potential of cyclic peptides as a novel approach for cancer treatment by targeting ubiquitin protein chains.Conclusions: This comprehensive investigation encompassed preformulation characterization, assessment of apoptotic activity, cell viability inhibition, pharmacokinetic profiling, analytical method development, determination of MTD, and evaluation of in vivo efficacy.The results provide valuable insights into the therapeutic potential of the novel cyclic peptides as anti-cancer agents, demonstrating their promise for further development and potential clinical applications.